Sanofi - ADR (SNY) News
Filter SNY News Items
SNY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SNY News Highlights
- SNY's 30 day story count now stands at 20.
- Over the past 12 days, the trend for SNY's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about SNY are DRUG, DE and AZN.
Latest SNY News From Around the Web
Below are the latest news stories about SANOFI that investors may wish to consider to help them evaluate SNY as an investment opportunity.
15 Undervalued Defensive Stocks For 2024In this article, we discuss the 15 undervalued defensive stocks for 2024. To skip the detailed overview of the market and defensive stocks, go directly to the 5 Undervalued Defensive Stocks For 2024. Defensive stocks are shares of companies that remain relatively stable during economic downturns as opposed to cyclical stocks. Defensive stocks usually outperform […] |
Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer ProgramSanofi (SNY) stops the development of tusamitamab ravtansine after a phase III study on the candidate for second-line metastatic non-small cell lung cancer fails to meet the primary endpoint. |
Pharma Stock Roundup: FDA Nod to AZN's Eplontersen, CRL to MRK's Cough CandidateFDA approves AstraZeneca (AZN) and Ionis' (IONS) Wainua (eplontersen) for ATTRv-PN and gives CRL to Merck's chronic cough candidate, gefapixant. |
Sanofi scraps a top ADC prospect after study setbackThe drug, acquired via a deal with ImmunoGen, was the most advanced experimental medicine in the French pharma’s pipeline. |
Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpointSanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival; tusamitamab ravtansine clinical development program will be discontinuedSanofi reinforces commitment to broader oncology development program including CEACAM5-directed antibody drug conjugates (ADC) with additional anticipated trials PARIS, December 21, 2023. Sanofi is disconti |
13 Most Promising Healthcare Stocks According to AnalystsIn this article, we discuss the 13 most promising healthcare stocks according to analysts. To skip the detailed overview of the healthcare sector, go directly to the 5 Most Promising Healthcare Stocks According to Analysts. The healthcare industry landscape is changing. While the COVID-19 pandemic was one of the most significant events that led to […] |
Sanofi: Information concerning the total number of voting rights and shares - November 2023Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,529,036,828 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regi |
UPDATE 2-US antitrust enforcers release final version of new merger guidelinesMergers in markets where there are a few big players will receive tougher scrutiny under guidelines that were finalized on Monday and released by the Justice Department, which works with the Federal Trade Commission to enforce antitrust law. The department said the new merger guidelines are aimed at encouraging fair, open and competitive markets. "These finalized guidelines provide transparency into how the Justice Department is protecting the American people from the ways in which unlawful, anticompetitive practices manifest themselves in our modern economy," Attorney General Merrick Garland said in a statement. |
Sanofi: The Current Price Makes No SenseA look at one of the leaders in the global autoimmune diseases treatment market |
7 Undervalued Biotech Stocks That are Flying Under the Clinical RadarWith so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. |